REGENXBIO, Inc. (RGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$7.20-2.83%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put RGNX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Resolve FDA rejection of RGX-121 and GSK sublicense dispute: Direct metric needs a verified mapping.
View ThesisRevenue growth is slowing — up about 12% over the past year and decelerating.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 65% in its worst 12-month stretch.
View RiskRGNX’s case rests on steady financial performance despite high risk and recent unprofitability. Q2 FY2026 revenue grew 406% year over year, and reported EPS beat consensus. The shares trade at 2.3× sales versus a 9.6× peer median and 2.8× historical multiple. The price reflects less growth than our forecast. The thesis risks unresolved FDA rejection of RGX-121 and the GSK sublicense dispute; their metric mapping is unverified. Our model puts the next-quarter miss probability near 45%. Peer multiples imply a price about 78% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. RGNX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering RGNX (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for RGNX in the last 4 months.
Continue this research
Compare RGNX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RGNX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put RGNX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Resolve regulatory and legal matters including GSK sublicense dispute and FDA r…
FDA hold impacts regulatory progress and objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $7.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $7.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Resolve regulatory and legal matters including GSK sublicense dispute and FDA r…
FDA hold impacts regulatory progress and objectives.
Threatens: Fund operations into early 2027
Concerns about cash runway affect funding operations.
Threatens: Address FDA rejection of RGX-121
Hold on RGX-121 CRL impacts regulatory objectives.
Threatens: Resolve GSK sublicense dispute
Lower price target due to regulatory uncertainty.
Advances: Address FDA rejection of RGX-121
Accelerated approval path for RGX-202 is positive.